Literature DB >> 26413608

CRISPR/Cas: A Faster and More Efficient Gene Editing System.

Bin Liu, Huifen Xu, Jiangfang Miao, Andy Zhang, Xiaojin Kou, Wen Li, Lin Zhou, Hong-Guang Xie, Pierre Sirois, Kai Li.   

Abstract

Gene editing technology has been at its mature stage with the successful development of TALENs and CRISPR/Cas enzymes. The genetically modified endonucleases of ZFNs, TALENs, and CRISPR/Cas are widely used in the development of genetically modified cells or organisms. Among the enzymes that possess gene editing ability, CRISPR/Cas is the latest member with high efficiency in gene editing and simplicity in cloning. This review discusses the discovery of CRISPR, the development of the CRISPR/Cas system, and its applications as a new gene editing system.

Mesh:

Year:  2015        PMID: 26413608     DOI: 10.1166/jnn.2015.9832

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  4 in total

Review 1.  CRISPR/Cas9 for overcoming drug resistance in solid tumors.

Authors:  Ali Saber; Bin Liu; Pirooz Ebrahimi; Hidde J Haisma
Journal:  Daru       Date:  2019-01-21       Impact factor: 3.117

2.  Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.

Authors:  Yunfei Liao; Lulu Chen; Yong Feng; Jacson Shen; Yan Gao; Gregory Cote; Edwin Choy; David Harmon; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2017-05-02

3.  CRISPR/Cas9-mediated editing of Δ5 and Δ6 desaturases impairs Δ8-desaturation and docosahexaenoic acid synthesis in Atlantic salmon (Salmo salar L.).

Authors:  Alex K Datsomor; Rolf E Olsen; Nikola Zic; Angelico Madaro; Atle M Bones; Rolf B Edvardsen; Anna Wargelius; Per Winge
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

4.  CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation.

Authors:  Bin Liu; Olivia Adaly Diaz Arguello; Deng Chen; Siwei Chen; Ali Saber; Hidde J Haisma
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.